Document Type: Research article
Pharmacology Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
Biotechnology Research center and School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy in the western world and exists as subtypes with very different clinical courses. Myeloid cell leukemia 1 (Mcl-1) is one member of Bcl-2 family proteins that has been shown to be expressed in various tissues and malignant cells, including CLL, where its expression is significantly associated with a failure to achieve complete remission following cytotoxic therapy.
Induction of apoptosis by prenylated coumarin, umbelliprenin, in Jurkat cells was previously shown. We examined whether umbelliprenin can down-regulate Mcl-1 gene and protein in Jurkat cells. In this regard cells were incubated by umbelliprenin, and then down- regulation of Mcl-1 gene was studied by Real Time PCR method. Moreover, down-regulation of Mcl-1 protein was studied by western blot analysis.
We showed that, expression of Mcl-1 mRNA was increased from 1 hour to 3 hours incubation٫ but this increase has a scale down pattern. Moreover umbelliprenin could inhibit Mcl-1 protein. In conclusion umbelliprenin treatment modulates Mcl-1 expression at both the transcriptional and posttranslational levels.